Photography, mixed media featured in exhibit at ASU Gammage

February 8, 2013

The next art exhibition at ASU Gammage will feature artwork by one group of artists and a solo artist.

Merrill A. Roberts, Jr. and the Artists of the Superstitions will showcase their work Feb. 20 through March 26. Rosa Parks Download Full Image

Roberts Jr.’s photographs include icons from the Civil Right Movement and the music industry, as well as New York scenes. Among his subjects are Coretta Scott King, Rosa Parks, Ted Kennedy, Duke Ellington Buddy Rich and Louis Armstrong.

“Art and its creation is the ability for us to see and understand clearly the inner nature of things by intuition far beyond the sight of the average person, to see and to feel within a deep sense of purpose in line with the magnitude and wonder of God’s creations,” said Roberts Jr.

A former member of the New York Working Press, Roberts Jr. is a self-taught photographer whose work has appeared in the New York Times, The Daily News, Billboard, Ebony, Jet and Essence magazines.

The second part of the exhibition features a variety of contemporary and traditional two-dimensional original compositions by the Artists of the Superstitions. Among these will include paintings, class and photography.

The Artists of the Superstitions is an organization comprised of talented artists who are committed to enriching the community’s art culture by providing opportunities for education and promotion of artistic expression.

Exhibit hours at ASU Gammage are 1 to 4 p.m., Mondays, or by appointment by calling 480-965-6912. The street address is 1200 S. Forest Ave., Tempe. Parking is available at meters around the perimeter of ASU Gammage. Entrance is through East Lobby Doors at the Box Office.

Media contact: 
Brad Myers
Art Exhibit Coordinator

Sharon Keeler

ASU, Mayo Clinic research teams receive individualized medicine grants

February 8, 2013

An external panel of venture capitalists, entrepreneurs and medical device manufacturers has awarded $100,000 grants to two joint Arizona State University-Mayo Clinic research teams that are working to apply personalized medicine to the treatment of Alzheimer’s disease and cerebral aneurysms.

The Center for Individualized Medicine at Mayo Clinic and the Office of Knowledge Enterprise Development (OKED) at Arizona State University joined in sponsoring the awards. More than 20 teams submitted proposals, with the winning teams including: Download Full Image

Development of nanobodies that target amyloid-β oligomers for individual diagnosis in Alzheimer’s disease: Michael Sierks, PhD, School for Engineering of Matter, Transport and Energy, Arizona State University; Terrone L. Rosenberry, PhD, and Pritam Das, PhD, both of Department of Neuroscience, Mayo Clinic.

The EndoVantage Interventional Suite (EVIS) for personalized clinical management of cerebral aneurysms: David Frakes, PhD, School of Biological and Health Systems Engineering and School of Electrical, Computer, and Energy Engineering, Arizona State University; Brian Chong, MD, Division of Neuroradiology, Mayo Clinic.

“The Center for Individualized Medicine at Mayo Clinic works to translate research breakthroughs into real-world applications that can improve health care for our patients,” said Jeremy L. Friese, director of New Business and Development in Mayo’s Center for Individualized Medicine. “We’re excited to see this kind of research collaboration be a component of the broader Mayo Clinic partnership with Arizona State University.”

“The quality of applications received for this opportunity reflects the superior quality of use-inspired research activities engaged by ASU and Mayo Clinic researchers in the area of health and personalized medicine,” said Sethuraman “Panch” Panchanathan, senior vice president of ASU’s Office of Knowledge Enterprise Development. “Through this collaborative effort, we are able to rapidly advance commercialization of novel ideas with the potential for significant economic development.”

Arizona Technology Enterprises (AzTE), the technology venturing arm of Arizona State University, is managing the initiative on behalf of ASU.

The competition was open to research pertaining to individualized medicine, broadly defined as “discovering and integrating the latest in genomic, molecular and clinical sciences into personalized care.” Funds can be used for a variety of activities, including prototype development, software or service development, pilot execution, company formation, or research endeavors leading to a commercialization product/ service.

Alzheimer’s disease team information: More than five million Americans now have Alzheimer’s disease (AD), and over the next 50 years the prevalence is expected to triple. The successful targeting of biomarkers is a critical component of individual diagnosis for many diseases, including AD. Unfortunately, biomarker targeting is not yet feasible for use with AD patients, and the development of appropriate protocols would have huge commercialization potential because of the staggering number of prospective AD patients. The applicants from both Mayo Clinic and ASU have long experience and strong complementary interests in the biochemical basis of AD and in reagents that would be useful in diagnosis and therapy.

Cerebral aneurysm team information: Current treatment planning for cerebral aneurysms (CAs) is primarily qualitative and driven by prior training, experience and convention. The EndoVantage Interventional Suite (EVIS) will be an innovative and ground-breaking new software platform that will radically enhance the personalized management of CAs. EVIS will utilize high-fidelity finite element medical device models and personalized clinical data to simulate the deployment of endovascular devices into patient-specific blood vessel models in real-time. State-of-the-art computational fluid dynamics will then be applied to simulate hemodynamic outcomes. EVIS will introduce a new endovascular treatment paradigm wherein quantitative engineering integrates with personalized treatment design.

The Center for Individualized Medicine discovers and integrates the latest in genomic, molecular and clinical sciences into personalized care for each Mayo Clinic patient. Visit for more information.

AzTE is a nonprofit organization which operates as the exclusive intellectual property management and technology transfer organization for ASU and its research enterprise. Established in 2003, AzTE is a wholly-owned subsidiary of the Arizona State University Foundation for A New American University. Comprising industry and university veterans, AzTE brings together ASU’s researchers and industry partners to transform discoveries into marketable products and services, taking innovation out of the lab and into the commercial marketplace. AzTE currently offers for licensing more than 300 novel technologies in the life and physical sciences.